Literature DB >> 25424791

A few years later. Update of the cost-effectiveness of infant pneumococcal vaccination in Dutch children.

Pepijn Vemer1, Maarten J Postma.   

Abstract

This study aimed to calculate the cost-effectiveness of infant pneumococcal vaccination in the Netherlands, using the 13-valent PCV13 vs. the currently used 10-valent PCV10. We adapted a previously published model, using recent estimates of epidemiological and efficacy data. In 12 scenarios, we explored the impact of different assumptions on the incremental cost-effectiveness ratio (ICER) of PCV13 over PCV10.Taking only direct effects on invasive pneumococcal disease into account, PCV13 was not found to be cost-effective at a price difference of €11 per dose. If herd protection, replacement and non-invasive disease were also taken into account, the ICER of PCV13 compared with PCV10 was below €30 000/QALY gained in 11 of 12 scenarios. PCV13 was considered dominant in the primary scenario with a price difference below €2.63 per dose.

Entities:  

Keywords:  Netherlands; PCV; Pneumococcal; cost-effectiveness; infant vaccination; vaccines

Mesh：

Substances：

Year:  2014        PMID： 25424791      PMCID： PMC4186027          DOI： 10.4161/hv.29008

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN： 2164-5515            Impact factor:   3.452


  23 in total

1.  [High vaccination coverage of the National Immunization Programme in the Netherlands].

Authors:  E Alies van Lier; Petra J Oomen; M W M Oostenbrug; S L N Zwakhals; Ingrid H Drijfhout; Pieter A A M de Hoogh; Hester E de Melker
Journal:  Ned Tijdschr Geneeskd       Date:  2009-05-16

2.  Comparative immunogenicity and efficacy of 13-valent and 7-valent pneumococcal conjugate vaccines in reducing nasopharyngeal colonization: a randomized double-blind trial.

Authors:  Ron Dagan; Scott Patterson; Christine Juergens; David Greenberg; Noga Givon-Lavi; Nurith Porat; Alejandra Gurtman; William C Gruber; Daniel A Scott
Journal:  Clin Infect Dis       Date:  2013-06-26       Impact factor: 9.079

3.  Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group.

Authors:  S Black; H Shinefield; B Fireman; E Lewis; P Ray; J R Hansen; L Elvin; K M Ensor; J Hackell; G Siber; F Malinoski; D Madore; I Chang; R Kohberger; W Watson; R Austrian; K Edwards
Journal:  Pediatr Infect Dis J       Date:  2000-03       Impact factor: 2.129

4.  The EQ-5D and the Health Utilities Index for permanent sequelae after meningitis: a head-to-head comparison.

Authors:  Rianne Oostenbrink; Henriëtte A A Moll; Marie-Louise Essink-Bot
Journal:  J Clin Epidemiol       Date:  2002-08       Impact factor: 6.437

5.  Efficacy of a pneumococcal conjugate vaccine against acute otitis media.

Authors:  J Eskola; T Kilpi; A Palmu; J Jokinen; J Haapakoski; E Herva; A Takala; H Käyhty; P Karma; R Kohberger; G Siber; P H Mäkelä
Journal:  N Engl J Med       Date:  2001-02-08       Impact factor: 91.245

6.  Invasive pneumococcal disease in the Netherlands: Syndromes, outcome and potential vaccine benefits.

Authors:  Angelique G S C Jansen; Gerwin D Rodenburg; Sabine C de Greeff; Eelko Hak; Reinier H Veenhoven; Lodewijk Spanjaard; Leo M Schouls; Elisabeth A M Sanders; Arie van der Ende
Journal:  Vaccine       Date:  2009-02-06       Impact factor: 3.641

7.  Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study.

Authors:  Roman Prymula; Pascal Peeters; Viktor Chrobok; Pavla Kriz; Elena Novakova; Eva Kaliskova; Igor Kohl; Patricia Lommel; Jan Poolman; Jean-Paul Prieels; Lode Schuerman
Journal:  Lancet       Date:  2006-03-04       Impact factor: 79.321

8.  Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia.

Authors:  Steven B Black; Henry R Shinefield; Stella Ling; John Hansen; Bruce Fireman; David Spring; Jack Noyes; Edwin Lewis; Paula Ray; Janelle Lee; Jill Hackell
Journal:  Pediatr Infect Dis J       Date:  2002-09       Impact factor: 2.129

9.  Enhanced decision support for policy makers using a web interface to health-economic models--illustrated with a cost-effectiveness analysis of nation-wide infant vaccination with the 7-valent pneumococcal conjugate vaccine in the Netherlands.

Authors:  G A A Hubben; J M Bos; D M Glynn; A van der Ende; L van Alphen; M J Postma
Journal:  Vaccine       Date:  2007-02-05       Impact factor: 3.641

Review 10.  How to compare the efficacy of conjugate vaccines to prevent acute otitis media?

Authors:  Philippe De Wals; Lonny Erickson; Béatrice Poirier; Jacques Pépin; Michael E Pichichero
Journal:  Vaccine       Date:  2009-03-10       Impact factor: 3.641
View more
  1 in total

1.  Modeling the cost-effectiveness of infant vaccination with pneumococcal conjugate vaccines in Germany.

Authors:  Alexander Kuhlmann; J-Matthias Graf von der Schulenburg
Journal:  Eur J Health Econ       Date:  2016-02-23
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.